Document:

bbu_ex104.htm

EXHIBIT 10.4

 

SUBSCRIPTION AGREEMENT

 

APAWTHECARY PETS USA

619 S. Ridgeley Drive, Los Angeles, CA 90036

 

A. Instructions.

 

Each person considering subscribing for the Shares should review the following instructions:

 

Subscription Agreement: Please complete, execute and deliver to the Company the enclosed copy of the Subscription Agreement. The Company will review the materials and, if the subscription is accepted, the Company will execute the Subscription Agreement and return one copy of the materials to you for your records.

 

The Company shall have the right to accept or reject any subscription, in whole or in part.

 

An acknowledgment of the acceptance of your subscription will be returned to you promptly after acceptance.

 

Payment: Payment for the amount of the Shares subscribed for shall be made at the time of delivery of the properly executed Subscription Agreement, or such date as the Company shall specify by written notice to subscribers (unless such period is extended in the sole discretion of the President of the Company), of a check or wire transfer of immediately available funds to the Company at the address set forth below or an account specified by the Company. The closing of the transactions contemplated hereby (the “Closing”) will be held on 90 days from June13, 2013 or such earlier date specified in such notice (unless the closing date is extended in the sole discretion of the President of the Company by up to an additional 90 days). There is no minimum aggregate amount of Shares which must be sold as a condition precedent to the Closing, and the Company may provide for one or more Closings while continuing to offer the Shares that constitute the unsold portion of the Offering.

 

B. Communications.

 

All documents and check should be forwarded to:

 

APAWTHECARY PETS USA

619 S. Ridgeley Drive, Los Angeles, CA 90036

 

THE PURCHASE OF SHARES OF Apawthecary Pets USA INVOLVES A HIGH DEGREE OF RISK AND SHOULD BE CONSIDERED ONLY BY PERSONS WHO CAN BEAR THE RISK OF THE LOSS OF THEIR ENTIRE INVESTMENT.

 

EVERY POTENTIAL INVESTOR PRIOR TO ANY INVESTMENT OR PURCHASE OF APAWTHECARY PETS USA’S SHARES SHOULD READ THE PROSPECTUS RELATING TO THIS OFFERING.

 
	 
	1
	

 
	 

 

SUBSCRIPTION AGREEMENT SIGNATURE PAGE

 

The undersigned (the “Subscriber”) hereby irrevocably subscribes for that number of Shares set forth below, upon and subject to the terms and conditions set forth in the Corporation’s Effective Final Prospectus filed on Form S-1 and dated on or around September 15, 2017.

 

Total Number of Shares to be Acquired: _____________________________

 

Amount to be Paid (price of $0.25 per Share): _____________________________

 

IN WITNESS WHEREOF, the undersigned has executed this Subscription Agreement

this ________ of ________________________________, 2018.

 

NAME: (PRINT) as it should appear on the Certificate: __________________________

 

ADDRESS:     _______________________________________________________________________

_______________________________________________________________________

 

If Joint Ownership, check one (all parties must sign above):

o Joint Tenants with Right of Survivorship

o Tenants in Common

o Community Property

 

If Fiduciary or a Business or an Organization, check one:

o Trust

o Estate

o Power of Attorney

 

Name and Type of Business Organization: ________________________________________

 

IDENTIFICATION AUTHENTICATION REQUIRED:

 

Below is my (circle one) Social Security # - Passport# - Drivers License# - Tax

ID# - Other ___________________

# ____________________________________________

 

SIGNATURE: ___________________________________

 

ACCEPTANCE OF SUBSCRIPTION

 

The foregoing Subscription is hereby accepted for and on behalf of APAWTHECARY PETS USA

this _______ day of ____________________________, 2018.

 

 

	
By:
	
 
	
 

	
 
	
Bradley Kersch, President
	
 

 

  

	
2Blueprint

 

 

CONSULTING
AGREEMENT

 

 

This
Consulting Agreement (herein referred to as “Agreement”) is made and entered
into on
December 8, 2017, effective as of January 1, 2018 (the
“Effective
Date”), by and between Monopar Therapeutics, Inc.
(herein referred to as “Monopar”), a Delaware corporation,
located at 5 Revere Dr., Suite 200, Northbrook, IL 60062, and pRx
Consulting, LLC (herein referred to as pRx), a Delaware corporation
located at # (each herein referred to as “Party” and collectively as
“Parties”).

 

 

RECITALS

 

 

WHEREAS, pRx
specializes in the field of clinical development, including but not
limited to: clinical trial design, statistical modeling, clinical
operations, regulatory strategy, investor due diligence, and the
duties of a Chief Medical Officer.

 

 

WHEREAS, Monopar
desires to contract with pRx to provide certain consultation
services as requested by Monopar, and pRx wishes to provide such
services to Monopar, upon the terms and conditions set forth
below.

 

 

NOW,
THEREFORE, in consideration of the premises and mutual covenants
contained herein, the Parties agree as follows:

 

 

1. 

Consulting Arrangement. pRx
agrees to perform consulting services as described herein upon the
terms and conditions herein set forth.

 

 

2. 

Term of Agreement. Subject to
the provision for early termination set forth below in Section 5 of this Agreement, this
Agreement shall commence as of the Effective Date and shall
continue for a period of twelve (12) months from the Effective Date
(the “Term”).
Either Party may terminate this Agreement without cause with
10-days’ prior written notice.

 

 

 

3. 

Duties of pRx.

 

 

 

3.1 

Specific Duties. pRx shall
provide consulting services to Monopar, such duties to include the
general duties of a Chief Medical Officer, clinical trial design,
statistical modeling, clinical operations oversight, regulatory
strategy, and investor due diligence, with such other specific
requirements as Monopar may specify from time to time during the
Term (herein referred to as the “Services”).

 

 

3.2 

pRx’s Obligations. The
president of pRx, Dr. P. Rioux, shall spend on the average over the
course of the Term one-and-a-half (1.5) work days per week working
on Monopar matters, be diligent in the performance of Services, and
be professional in its commitment to meeting its obligations
hereunder. pRx represents and warrants that pRx is not party to any
other existing agreement, which any of them would prevent pRx from
entering into this Agreement or which would adversely affect this
Agreement. pRx shall not perform Services for any other individuals
or entities in direct competition with Monopar, except as provided
for by mutual written agreement of the Parties. pRx shall not
perform services for any party

	

-
1
-

 

 

 

which
would require or facilitate the unauthorized disclosure of any
confidential or proprietary information of Monopar.

 

 

3.3 

Reporting. pRx will report to
and liaise with Andrew P. Mazar, Ph.D., Chandler Robinson, M.D.,
and/or any other assigned Monopar employee or consultant as may be
designated in writing by Monopar.

 

 

3.4 

Compensation. Monopar shall pay
pRx as follows:

 

 

a.            Four
thousand dollars ($4,000) per month payable within thirty (30) days
of the end of each month.

 

b.            Dr.
P. Rioux, president of pRx Consulting, LLC shall be granted stock
options to purchase up to 32,004 shares of Monopar’s common
stock at an exercise price of $6.00. Such stock option shall vest
as follows: on January 1, 2018, options to purchase up to 12,000
shares; and options to purchase up to 1,667 shares on the
1st of each subsequent month
thereafter. Such vesting shall terminate upon the termination of
this Agreement. The number of shares, the exercise price thereof
and the rights granted under this Agreement are subject to
adjustment and modification as provided in the Monopar Therapeutics
Inc. 2016 Stock Incentive Plan.

 

 

pRx
shall not be reimbursed, and is responsible for the facilities and
equipment necessary to perform Services required under this
Agreement.

 

 

4. 

Reimbursement of Other
Expenses. So long as Monopar’s prior approval has been
obtained, Monopar shall promptly reimburse pRx for all direct
expenses incurred in providing the Services to Monopar pursuant to
this Agreement, including travel, meals and lodging. The invoice
submitted by pRx pursuant to this Section 4 shall also include a detail of
all reimbursable expenses incurred during the period covered by
such invoice.

 

 

5. 

Termination of Agreement - Failure to
perform. In the event that pRx ceases to perform the
Services or breaches its obligations as required hereunder for any
reason, Monopar shall have the right to immediately terminate this
Agreement upon notice to pRx and to enforce such other rights and
remedies as it may have as a result of said breach.

 

 

6. 

Certain Liabilities. It is
understood and agreed that pRx shall be acting as an independent
contractor and not as an agent or employee of, or partner, joint
venturer or in any other relationship with Monopar. pRx will be
solely responsible for all insurance, employment taxes, FICA taxes
and all obligations to governments or other organizations for it
and its employees arising out of this consulting assignment. pRx
acknowledges that no income, social security or other taxes shall
be withheld or accrued by Monopar for pRx’s or its
employees’ benefit. pRx assumes all risks and hazards
encountered in the performance of duties by it or its employees
under this Agreement. Unless Monopar has provided prior written
approval, pRx shall not use any sub-contractors to perform
pRx’s obligations hereunder. pRx shall be solely responsible
for any and all injuries, including death, to all persons and any
and all loss or damage to property, which may result from
performance under this Agreement.

	

-
2
-

 

 

 

7.

Indemnities. pRx hereby agrees
to indemnify Monopar and hold Monopar harmless from and against all
claims (whether asserted by a person, firm, entity or governmental
unit or otherwise), liabilities, losses, damages, expenses, charges
and fees which Monopar may sustain or incur arising out of or
attributable to any breach, gross negligence or willful misconduct
by pRx or its employees or contractors, as applicable, in the
performance under this Agreement. Monopar hereby agrees to
indemnify pRx and hold pRx harmless from and against all
liabilities, losses, damages, expenses, charges and fees which pRx
may sustain or incur by reason of any claim which may be asserted
against pRx by any person, firm, corporation or governmental unit
and which may arise out of or be attributable to any gross
negligence or willful misconduct by Monopar or its employees or
contractors, as applicable, in the performance of this
Agreement.

 

 

8. 

Warranties. The Services shall
be performed in a professional manner, consistent with industry
standards. In performing the Services, neither pRx nor any of its
employees shall make any unauthorized use of any confidential or
proprietary information of any other party or infringe the
intellectual property rights of any other party.

 

 

9. 

Arbitration. Any controversy or
claim between Monopar and pRx arising out of or relating to this
Agreement, or the breach thereof, shall be submitted to arbitration
in accordance with the rules of the American Arbitration
Association. The site of the arbitration shall be Chicago, IL, and
except as provided herein the arbitration shall be conducted in
accordance with the Rules of the American Arbitration Association
prevailing at the time the demand for arbitration is made
hereunder. At least one member of the arbitration panel shall be an
expert knowledgeable in the area of biopharmaceutical clinical
development. Judgment upon any award rendered by the arbitrator(s)
may be entered in any court of competent jurisdiction and shall be
binding and final. The cost of arbitration shall be borne by the
losing Party, as determined by the arbitrator(s).

 

 

10. 

Confidential Information. pRx
has executed the attached confidential disclosure agreement
referenced herein as Appendix
A prior to commencement of the Services. pRx hereby
represents and warrants that the obligations thereunder shall be
binding upon it and its employees, and that it shall obtain written
commitments from such employees thereto.

 

 

 

11. 

Inventions. pRx agrees that all
ideas, developments, suggestions and inventions which an employee
or other parties contracted conceive or reduce to practice arising
out of or during the course of performance under this Agreement
shall be the exclusive property of Monopar and shall be promptly
communicated and assigned to Monopar. pRx shall require any
employees of or other parties contracted by pRx to disclose the
same to pRx and to be bound by the provisions of this paragraph.
During the period of this Agreement and thereafter at any
reasonable time when called upon to do so by Monopar, pRx shall
require any employees of or other parties contracted by pRx to
execute patent applications, assignments to Monopar (or any
designee of Monopar ) and other papers and to perform acts which
Monopar believes necessary to secure to Monopar full protection and
ownership of the rights in and to the services performed by pRx
and/or for the preparation, filing and prosecution of applications
for patents or inventions made by any employees of or other parties
contracted by pRx hereunder. The decision to file patent
applications on inventions made by any employees of or other
parties contracted by pRx shall be made by

	

-
3
-

 

 

 

Monopar
and shall be for such countries as Monopar shall elect. Monopar
agrees to bear all the expense in connection with the preparation,
filing and prosecution of applications for patents and for all
matters provided in this paragraph requiring the time and/or
assistance of pRx as to such inventions.

 

 

12. 

Miscellaneous.

 

 

12.1 

Notice. Any notices to be given
hereunder by either Party to the other may be effectuated, in
writing, by personal delivery or by mail, registered or certified,
postage prepaid, with return receipt requested, or by electronic
mail. Mailed notices shall be addressed to the Parties at the
following addresses:

 

 

If to
Monopar:  
                                           

Monopar
Therapeutics Inc.

 

5 Revere Dr., Suite
200

 

Northbrook, IL,
60062

 

Attention: Chandler
Robinson, MD MBA MSc

 

Email: #

 

 

If to
pRx:   pRx Consulting, LLC

                  
#

Attention: Patrice
Rioux, MD, PhD

Email:
#

 

 

or at
such other addresses as either Monopar or pRx may designate by
written notice to each other. Notices delivered personally shall be
deemed duly given on the date of actual receipt; mailed notices
shall be deemed duly given as of the fourth day after the date so
mailed. If sent by electronic mail, such notice will be deemed
given upon confirmation of receipt by recipient.

 

 

12.2 

Waiver of Breach. The waiver by
either Party to a breach of any provision in this Agreement cannot
operate or be construed as a waiver of any subsequent breach by
either Party.

 

 

 

12.3 

Severability. If any provision
of this Agreement is determined by a court of competent
jurisdiction to be invalid or unenforceable, that provision shall
be deemed modified to the extent necessary to make it valid or
enforceable, or if it cannot be so modified, then severed, and the
remainder of the Agreement shall continue in full force and effect
as if the Agreement had been signed with the invalid portion so
modified or severed.

 

 

12.4 

Choice of Law. This Agreement
has been made and entered into in the State of Illinois, and the
laws of such state, excluding its choice of law rules, shall govern
the validity and interpretation of this Agreement and the
performance due

	

-
4
-

 

 

 

hereunder.
The losing party in any dispute hereunder shall pay the attorneys'
fees and disbursements of the prevailing party.

 

12.5 

integration.
The drafting, execution and delivery
of this Agreement by the Parties have been induced by no
representations, statements, warranties or agreements other than
those expressed herein. This Agreement embodies the entire
understanding of the Parties, and there are no further or other
agreements or understandings, written or oral, in effect between
the Parties relating to the subject matter hereof unless expressly
referred to herein.

 

12.6 

Modification.
This Agreement may not be modified
unless such is in writing and signed by both Parties to this
Agreement.

 

 

 

12.7 

Assignment.
pRx shall not be permitted to assign
this Agreement to any other person or entity without the prior
written consent of Monopar. pRx hereby agrees that Monopar shall be
permitted to assign this Agreement to any affiliate of Monopar.
This Agreement shall be binding upon and shall inure to the benefit
of the successors and permitted assigns of the
parties.

 

12.8 

Survival.
The provisions of Sections 7, 8, 9, 10, and
11 shall survive expiration or
termination of this Agreement for any reason. Expiration or
termination of this Agreement shall not affect Monopar's
obligations to pay any amounts that may then be due to
pRx.

 

 

IN
WITNESS WHEREOF, the Parties hereto have executed this Agreement as
of the day and year first above written.

 

 

 
ACCEPTED
AND AGREED TO:

 

 

 
pRx
Consulting LLC       
           
           
           
           
           
           
    Monopar Therapeutics
Inc.

 

  /s/ Patrice
Rioux                                                                                      

 /s/
Chandler Robinson

 

 

 

 
BY: PATRICE RIOUX. MD, PHD       
           
           
           
           
     BY: CHANDLER ROBINSON
 
ITS:
PRESIDENT           
           
           
           
           
           
           
   ITS: CHIEF EXECUTIVE OFFICER

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

                 

 

 

 

 

 

 

 

 

 

 

 

 

 

APPENDIX
A

 

 

See
executed CDA attached

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

- 6
-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}]]